{"filing":{"accession_number":"0001104659-26-117937","cik":"0001356576","ticker":"SUPN","company_name":"SUPERNUS PHARMACEUTICALS, INC.","form":"8-K","filing_date":"2026-10-21","report_date":"2026-10-21","primary_document":"tm2628092d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465926117937/tm2628092d1_8k.htm"},"events":[{"id":36926,"run_id":34041,"accession_number":"0001104659-26-117937","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The disclosure announces FDA recognition of seven-year orphan-drug exclusivity for ONAPGO (apomorphine HCl) and submission of a supplemental NDA for a second supplier. This is a regulatory and operational milestone that protects market exclusivity for a key product and addresses supply chain resilience, both material to investors assessing the company's competitive position and product sustainability. While not fitting a specific named category, this is clearly an operational/strategic business event involving regulatory approval and product supply strategy.","company_name":"SUPERNUS PHARMACEUTICALS, INC.","ticker":"SUPN","filing_date":"2026-10-21","form":"8-K","submitted_at":null,"items":[{"id":41489,"accession_number":"0001104659-26-117937","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces FDA recognition of seven-year orphan-drug exclusivity for ONAPGO (apomorphine HCl) and submission of a supplemental NDA for a second supplier. This is a regulatory and operational milestone that protects market exclusivity for a key product and addresses supply chain resilience, both material to investors assessing the company's competitive position and product sustainability. While not fitting a specific named category, this is clearly an operational/strategic business event involving regulatory approval and product supply strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-22T10:05:57.097206+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":41489,"accession_number":"0001104659-26-117937","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces FDA recognition of seven-year orphan-drug exclusivity for ONAPGO (apomorphine HCl) and submission of a supplemental NDA for a second supplier. This is a regulatory and operational milestone that protects market exclusivity for a key product and addresses supply chain resilience, both material to investors assessing the company's competitive position and product sustainability. While not fitting a specific named category, this is clearly an operational/strategic business event involving regulatory approval and product supply strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-22T10:05:57.097206+00:00","company_name":"SUPERNUS PHARMACEUTICALS, INC.","ticker":"SUPN","filing_date":"2026-10-21"}]}